January 28, 2021 Acad, Gov/Utilities Environ, Ag./Food & Bev Life Science Tools Liq. Handling & Robotics

QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing

Germantown, Maryland, and Hilden, Germany, January 28, 2021 – QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products. The use of dPCR in the worldwide surveillance of COVID-19 is an additional step towards making digital PCR (dPCR) an affordable and standard instrument for a host of applications... Read more

January 25, 2021 Acad, Gov/Utilities Licensing, IP, and Legal M&A, Partnerships Product Launch

Roche renews partnership with Sysmex to deliver haematology testing solutions

This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of... Read more

January 19, 2021 Acad, Gov/Utilities Atomic Spectroscopy Lab Top-10 M&A, Partnerships Microscopy

Shimadzu signs a collaboration agreement with TOTAL, a major Energy player and two European universities.Toward the Development of an Innovative “Oxygenated compound analysis system” for Biofuel Research

Shimadzu signs a collaboration agreement with TOTAL, a major Energy player and two European universities.Toward the Development of an Innovative “Oxygenated compound analysis system” for Biofuel Research Read more

January 12, 2021 Acad, Gov/Utilities M&A, Partnerships

Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab

Basel, 12 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron’s casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed. The US government... Read more

January 5, 2021 Acad, Gov/Utilities

Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer

Basel, 5 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung... Read more

December 21, 2020 Acad, Gov/Utilities Bio/Pharma/CRO

Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness

Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies More than half of participants in the faricimab personalised dosing arms had extended time between treatments to 16 weeks at year one – the first... Read more

December 14, 2020 Acad, Gov/Utilities Licensing, IP, and Legal

FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis

Basel, 14 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The... Read more

December 14, 2020 Acad, Gov/Utilities

GE Healthcare and St. Luke’s University Health Network Accelerate Breast Cancer Care with First One-Stop Clinic in the U.S.

St. Luke’s University Health Network in Pennsylvania to serve as national model for rapid diagnostic breast cancer centers One-stop breast clinics worldwide have revolutionized patient outcomes, with same-day results for 75 percent of patients and 80 percent patient satisfaction at the flagship clinic[1] CHICAGO, IL, December 14, 2020 – GE Healthcare (NYSE: GE) today announced... Read more